Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

Recruiting

Phase 1

Venetoclax, Dexamethasone, Bortezomib, DaratumumabVenetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07513129

Conditions

T-cell Acute Lymphoblastic Leukemia

Lymphoma

Eligibility Criteria

Sex: All

Age: 12 - 30

Healthy Volunteers: Not accepted

Interventions

Venetoclax

Dexamethasone

Bortezomib

Daratumumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-02. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-06-17.